EP0928790A1 — Thiazole derivatives
Assigned to F Hoffmann La Roche AG · Expires 1999-07-14 · 27y expired
What this patent protects
Compounds of formula I as well as pharmaceutically usable salts and esters thereof, wherein R 1 , R 2 and R 3 have the significance given in claim 1, inhibit the binding of adhesive proteins to the surface of different types of cell and accordingly influence cell-cell and cel…
USPTO Abstract
Compounds of formula I as well as pharmaceutically usable salts and esters thereof, wherein R 1 , R 2 and R 3 have the significance given in claim 1, inhibit the binding of adhesive proteins to the surface of different types of cell and accordingly influence cell-cell and cell-matrix interactions. They can be used in the form of pharmaceutical preparations for the control or prevention of neoplasms, tumour metastasing, tumour growth, osteoporosis, Paget's disease, diabetic retinopathy, macular degeneration, restenosis following vascular intervention, psoriasis, arthritis, fibrosis, kidney failure as well as infection caused by viruses, bacteria or fungi.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.